Academic Studies

GI Dynamics has announced that it has entered into separate research collaborations with GlaxoSmithKline and Medtronic in an effort to understanding how EndoBarrier® works in relation to diabetes.

So despite initiative after initiative, the leviathon that is the NHS, the institution that above all others needs to have professional procurement infrastructure, sounds like a basket case of in-fighting, suspicion of the private sector and no outcome controls. So says a new expert report.

While the toxicology work continues, it seems implant data is still saying the same thing, that PIP implants rupture more frequently than other implants, that in most cases there is no reaction, and when there is a reaction it’s obvious. Most significantly data confirms no resultant cancer.

Can the colour of your intraocular lenses affect your circadian rhythm and general health? Really? Our disbelief is suspended temporarily as Abbott Medical cites clinical evidence that it can.

A coating of selenium nanoparticles significantly reduces the growth of Staphylococcus aureus on polycarbonate, a material common in implanted devices such as catheters and endotracheal tubes, engineers at Brown University report in a new study.

Which ever technology the future of atrial fibrillation therapies lies in, this new report from UK consulting firm Cambridge Design Partnership claims to have it covered. And its available on request!

68% of patients surveyed don’t think the medical devices industry is good at practising ethical marketing. Should we be surprised? Interesting survey from a global patient group audience.

If we can understand how bacteria protect themselves against immune responses and antibiotics, we may be able to work out how to break down their defences or even stop the formation of these so-called biofilms in the first place. Researchers at York University think that’s a possibility.

Pardon our irreverence, but there’s a sitcom in here somewhere. The automated “housecall” is an obvious component in the provision of tomorrow’s healthcare, but the potential to get it wrong presents a minefield in which only certain patients with certain conditions will form the first wave.

It’s all getting a bit heated as Medtronic and St. Jude lock horns again, this time over the Hauser publication in Heart Rhythm journal.

Study into Cancer risk in the first seven years after Metal-on-Metal Hip Replacement compared with other bearings and general population: linkage study between the National Joint Registry of England and Wales and hospital episode statistics.

A study, presented at the ACC meeting in Chicago, shows that low BMI patients are at higher risk of complications during or shortly after ICD implantation.

Industry body Eucomed fights the corner for the innovative medtech company by proposing that unless procurement gets smarter we’ll be driven to lowest common denominator solutions by short term cost containment and centralisation.

RSM study shows just how strange we humans are, as it suggests NHS could save millions by asking patients to write down their appointment times.

It seems the balance of power lies with the healthcare provider in USA as prices of procedures far outstrip overseas markets despite medical device companies often selling their products for lower prices in USA.

St Jude is pretty bullish about FFR measurement as a diagnostic tool in assessing coronary artery disease, based on favourable outcome from previous studies. It’s now supporting a country-specific evaluation of the cost effectiveness of an FFR-guided intervention strategy for patients with multivessel coronary artery disease in Japan, China, India, Korea, and Australia.